Allopurinol

Allopurinol is a medication that lowers the body's production of uric acid, and it belongs to the class of xanthine oxidase inhibitors ^[1]. Chemically it is an analogue of hypoxanthine, one of the natural purine molecules the body handles as it breaks down genetic material, and it emerged from purine research at the Wellcome laboratories associated with the scientists Gertrude Elion and George Hitchings ^[1]. Introduced for gout in the 1960s, it has become the cornerstone of treatment for conditions caused by excess uric acid ^[1][4].

Its principal use is the long-term management of gout, a painful arthritis caused when uric acid crystallizes in the joints; by keeping uric acid low, allopurinol prevents the recurrent attacks and deposits that characterize the disease ^[4]. Treatment guidelines recommend it as a first-line urate-lowering therapy, begun at a low dose and adjusted to reach a target uric acid level ^[4]. It is also used to prevent uric acid kidney stones and to guard against tumor lysis syndrome, the dangerous release of uric acid that can occur when many cancer cells are destroyed by chemotherapy ^[1]. Once absorbed, allopurinol is rapidly converted to a long-lasting active metabolite called oxypurinol, which carries out much of its uric-acid-lowering effect and is cleared by the kidneys ^[2].

Allopurinol is taken by mouth, is inexpensive and available generically, and is listed by the World Health Organization as an essential medicine ^[1]. It is generally well tolerated, but a small number of people develop a skin rash, and rarely a severe and potentially life-threatening hypersensitivity reaction can occur ^[3]. This serious reaction is strongly linked to a genetic variant called HLA-B*58:01, which is more common in some populations, and testing for this marker is recommended in higher-risk groups before starting the drug ^[3].

Allopurinol is prescription only. Most people tolerate it well, but it can trigger a gout flare when first started, so a short course of colchicine or an anti-inflammatory is often given alongside it for the first several months. Common side effects include rash, stomach upset, and mild liver enzyme changes. The serious concern is allopurinol hypersensitivity syndrome, including DRESS and Stevens-Johnson syndrome; the risk is higher in people who carry the HLA-B*58:01 gene variant and in those with kidney impairment. It interacts dangerously with azathioprine and mercaptopurine because it blocks their breakdown and can cause severe bone marrow suppression; it also raises rash risk with amoxicillin or ampicillin and can potentiate warfarin.

The dangerous interaction is with azathioprine and mercaptopurine. Both rely on xanthine oxidase for inactivation, and allopurinol blocks that enzyme, raising active thiopurine exposure several-fold and producing profound, sometimes fatal bone marrow suppression. This is why the pairing is generally avoided, and why it needs deliberate thiopurine dose reduction and blood count surveillance where a prescriber judges it unavoidable.

Allopurinol slows clearance of other xanthine oxidase substrates too. Didanosine exposure roughly doubles, and theophylline levels rise at higher allopurinol doses.

Ampicillin and amoxicillin given during allopurinol treatment produce rash considerably more often than either drug alone.

Thiazide diuretics and ACE inhibitors increase the risk of allopurinol hypersensitivity syndrome, particularly where renal function is reduced. Warfarin effect can be potentiated, and cyclosporine concentrations have been reported to rise.

Checking a whole stack? Run it through interactions + stacks.

Allopurinol emerged from the landmark purine research of Gertrude Elion and George Hitchings at Burroughs Wellcome, work that would later earn them the 1988 Nobel Prize in Physiology or Medicine. Originally studied in the context of cancer therapy, where it was used to protect the anticancer drug mercaptopurine from breakdown, the compound was found to be a potent inhibitor of xanthine oxidase and thus a means of lowering uric acid. It entered clinical use for gout in the 1960s and quickly became the standard urate-lowering therapy. Today it appears on the World Health Organization's List of Essential Medicines and remains one of the most prescribed drugs in its class worldwide.

More than half a century after its introduction, allopurinol is still considered the cornerstone of long-term gout management, valued for its effectiveness, low cost, and extensive track record. When titrated to a serum urate target, it can dissolve existing crystal deposits over time and sharply reduce the frequency of painful flares. The large FAST trial reinforced confidence in its long-term cardiovascular safety, finding no increased risk relative to febuxostat in older gout patients. Its main cautions are well understood: dosing must account for kidney function, and rare but serious hypersensitivity reactions are strongly linked to the HLA-B*58:01 gene variant, which is why screening is advised in higher-risk populations.